In this article, we examine why Canada has become a strategic launchpad for FinTech and crypto founders, and how executive ...

Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.

The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival ...

Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2 nd Line efficacy evaluable population of 12 months (n=9) Median OS of Intent to Treat population (1L ...

Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...

What Is Acute Myeloid Leukemia? Acute myeloid leukemia (AML) is a type of blood cancer that starts in your bone marrow, which is the soft inner part of your bones where all your blood cells are made.

Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. It affects the ability of your bone marrow to produce normal-functioning white blood cells (WBCs). The risk of this type of ...

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification Overall, a history of any infectious disease was associated ...

Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...